Chart-Typ:
Zeitraum:
| QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention | New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor | Neue Studie unterstützt den Einsatz von QuantiFERON-TB Gold Plus bei immungeschwächten Personen und anderen Hochrisikogruppen in verschiedenen Settings Ergebnisse zeigen, dass der QuantiFERON-Test... ► Artikel lesen |
| Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen |
| Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen |
| Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025 | Conference Call to be Held at 8:00am ET
Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October... ► Artikel lesen |
| Immunovant Inc.: Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) | Phase 3 studies of batoclimab in thyroid eye disease (TED) each failed to meet their primary endpoint; safety results were consistent with previous findingsPatients in the TED studies demonstrated... ► Artikel lesen |
| Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AQUAPORIN A/S finden Sie auf Wallstreet Online.